Combination treatment for bone and soft tissue sarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug, HS-20093, combined with other treatments for people with advanced bone or soft tissue sarcoma. The goal is to see if these combinations can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have advanced or metastatic osteosarcoma or soft tissue sarcoma that has not responded to standard treatment, or you are in a group that has not yet received treatment for advanced disease.
- You have at least one measurable tumor outside the brain.
- You are willing to provide a tumor tissue sample (fresh or from a previous biopsy).
- You are generally able to care for yourself (ECOG performance status 0-1) and expected to live at least 12 weeks.
- You agree to use effective contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new combination of four treatments (an experimental drug, two chemo-like drugs, and radiation) for advanced soft tissue sarcoma that hasn't responded to earlier treatments. The goal is to see if this combination can help shrink or slow the cancer.
This trial tests a combination of radiation therapy and two drugs (anlotinib and penpulimab) given before surgery for soft tissue sarcoma. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests an experimental drug, SOT106, that targets a specific marker on sarcoma cells. It aims to see if the drug is safe and effective in treating advanced osteosarcoma or soft tissue sarcoma when other treatments have not helped.
This trial tests a new combination therapy: an injected virus (OVV-01) alongside an immunotherapy drug (AK112) for people with advanced soft tissue sarcoma that hasn't responded to usual treatments. The aim is to see if this approach can help shrink tumors or slow their growth.
This trial tests a new drug called bexmarilimab combined with doxorubicin for people with soft-tissue sarcoma that has spread to other parts of the body. The goal is to see if the combination is safe and works better than doxorubicin alone.
This Phase 2 trial studies HS-20093 in adults with osteosarcoma or other sarcomas that came back or did not respond to standard treatment. It aims to see how well the drug works and whether it is safe for people whose cancer has progressed.
Hear when a new Osteosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.